Use of Cystic Fibrosis inhaled medication after Elexacaftor/Tezacaftor/Ivacaftor in comparison to before
Is it cost-effective to use genetic tools to predict how well patients with cystic fibrosis will respond to treatment?
Predicting Risk-Adjusted Incidence Rates of Methicillin-Resistant Staphylococcus aureus and Pseudomonas aeruginosa in the Cystic Fibrosis Programs in the United States
Comparing continuous glucose monitoring to self-monitoring of blood glucose in the management of cystic fibrosis related diabetes; a systematic review and meta-analysis
